Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 1 1

Status

Completed 4Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 72Lymphoid 68Gastrointestinal 63Other hematologic neoplasm 63Genitourinary 48Breast 42CNS 29Gynecologic 27Myeloid 26Plasma cell 26Dermatologic 20Head & Neck 17Endocrine 16Classical hematology 15Sarcoma 14Other solid neoplasm 12NET 8Tumor-Agnostic 5

Conditions

Neoplasms 3Neoplasm Metastasis 1Carcinoma 1

Interventions

trastuzumab deruxtecan 1pembrolizumab 1margetuximab 1lenvatinib 1larotrectinib 1atezolizumab 1Trastuzumab 1Pemetrexed 1Carboplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has announcements × Tumor-Agnostic × Clear all
NCT02637687 2025-06-22

SCOUT

Bayer

Phase 1/2 Active not recruiting
154 enrolled 2 FDA
Tumor-Agnostic

Neoplasms

NCT02492711 2025-03-17

SOPHIA

MacroGenics

Phase 3 Completed
624 enrolled 17 charts 1 FDA
Tumor-Agnostic

Neoplasm Metastasis

NCT02564900 2024-01-22

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

Daiichi Sankyo

Phase 1 Completed
292 enrolled 35 charts 1 FDA
Tumor-Agnostic

Neoplasms

NCT02501096 2023-07-20

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Eisai Inc.

Phase 1/2 Completed
357 enrolled 28 charts 1 FDA
Tumor-Agnostic

Neoplasms

NCT02367781 2021-08-09

IMpower130

Hoffmann-La Roche

Phase 3 Completed
723 enrolled 28 charts 1 FDA
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡